Sign up
Pharma Capital

Canadian medical marijuana company Aphria pegs C$225mln war chest to build new facilities

Aphria to build a C$55mln cannabis extraction center in Ontario as Canada gears up to begin legal pot sales by late summer
Canada's Senate voted to pass Bill C-45 — landmark legislation to legalize recreational marijuana

With the Canadian Senate voting ‘Yes’ Thursday to legalize recreational cannabis, Canadian medical marijuana growers are all chasing first-mover advantage and global expansion. Aphria Inc (TSE:APH) was quick off the block with its announcement Thursday that it will make a big investment in Leamington, Ontario.

The company, which has an eye on global expansion, said it is raising C$225mln to pay for new cannabis facilities in Canada, as well as potential acquisitions. Some of the funds will be plowed into a new C$55mln extraction facility in Leamington, Ontario that will use a variety of methods to produce concentrated cannabis products like oils.

READ: A game-changing vote: Canadian senate votes ‘Yes’ to legalize recreational cannabis

"The Extraction Centre of Excellence will give Aphria a significant competitive advantage in cannabis concentrates, which are expected to be a significant product category," said Aphria CEO Vic Neufeld, in a statement. "This facility will be the centre of industry-leading R&D and commercial production of next generation cannabis concentrate products."

The Canadian firm also said it plans to spend an additional C$20mln at its Aphria Diamond facility to increase capacity by 20 tonnes annually and allow for alternative growing techniques, and C$10mln to add 10 tonnes of capacity to its Aphria One operation.

Canadian producers like Aphria are pushing really hard to take that first-mover advantage as the country gets all set to legalize marijuana sales. The Canadian Senate voted Thursday to pass Bill C-45 — the landmark legislation to legalize recreational marijuana — by a vote of 56 to 30, with one abstention.

Aphria is one of Canada's low-cost producers and sells medical cannabis. It is in Leamington, Ontario, the greenhouse capital of Canada.

Register here to be notified of future Company articles
View full profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.